ORXOY

Orexo AB (publ) [ORXOY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ORXOY Stock Summary

In the News

02:12 27 Sep 2023 ORXOY

MODIA™ paper published in the Journal of Medical Internet Research Mental Health

UPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Treatment of Opioid Use Disorder:  Development Study," in the Journal of Medical Internet Research (JMIR) Mental Health.

02:47 27 Sep 2023 ORXOY

Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial

UPPSALA, Sweden, July 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124.

02:21 27 Sep 2023 ORXOY

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

UPPSALA, Sweden, July 1, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination with sublingual buprenorphine/naloxone, as part of a clinician-supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).

02:50 27 Sep 2023 ORXOY

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use...

10:45 27 Sep 2023 ORXOY

Orexo calls for redemption of its outstanding bonds and obtains temporary waiver

UPPSALA, Sweden, Feb. 5, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK 500,000,000 senior unsecured callable floating rate bonds 2017/2021 with ISIN SE0010494450 (the "Bonds")...

12:10 27 Sep 2023 ORXOY

Orexo has successfully issued senior unsecured callable floating rate bonds

UPPSALA, Sweden, Feb. 4, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the amount of SEK 500 million, under a framework of SEK 1,000 million with final maturity in February...

02:15 27 Sep 2023 ORXOY

Orexo contemplates issue of senior unsecured callable floating rate bonds

UPPSALA, Sweden, Feb. 1, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income investor meetings in the Nordics, commencing on 1 February 2021. An issue of SEK denominated senior...

02:17 27 Sep 2023 ORXOY

Orexo strengthens IP rights for overdose rescue drug OX124

UPPSALA, Sweden, Jan. 27, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship pharmaceutical pipeline asset OX124, a naloxone rescue medication for the treatment of...

ORXOY Financial details

Company Rating
Buy
Market Cap
54.2M
Income
-194.8M
Revenue
633.5M
Book val./share
3.6
Cash/share
7.3
Dividend
-
Dividend %
-
Employees
120
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-1.48
Forward P/E
-
PEG
1.15
P/S
0.96
P/B
2.32
P/C
0.1
P/FCF
-2.9
Quick Ratio
0.83
Current Ratio
1.87
Debt / Equity
4.18
LT Debt / Equity
4
-
-
EPS (TTM)
-5.67
EPS next Y
-
EPS next Q
-
EPS this Y
-20.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-4.43%
Revenue Q/Q
-0.69%
EPS Q/Q
-80.11%
-
-
-
-
SMA20
-44.44%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-21%
ROE
-105%
ROC
-0.36%
Gross Margin
84%
Oper. Margin
-35%
Profit Margin
-31%
Payout
-
Shs Outstand
72.53M
Shs Float
21.64M
-
-
-
-
Target Price
-
52W Range
0.76-2.82
52W High
-
52W Low
-
RSI
-
Rel Volume
38
Avg Volume
43
Volume
1.63K
Perf Week
-21.81%
Perf Month
-55.56%
Perf Quarter
-
Perf Half Y
-55.56%
-
-
-
-
Beta
0.665165
-
-
Volatility
0.07%, 0.35%
Prev Close
-21.81%
Price
0.76
Change
-21.81%

ORXOY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
22.6624.419.2916.4618.17
Net income per share
3.996.33-2.45-6.51-5.17
Operating cash flow per share
78.290.49-6.67-4.56
Free cash flow per share
6.97.37-5.03-8.21-5.25
Cash per share
17.0723.5914.6914.6910.24
Book value per share
13.7820.416.2410.195.64
Tangible book value per share
10.7717.119.422.94-0.68
Share holders equity per share
13.7820.416.2410.195.64
Interest debt per share
9.7510.518.9316.8616.52
Market cap
1.94B2.14B1.52B1.25B620.23M
Enterprise value
1.67B1.66B1.31B1.29B1.03B
P/E ratio
14.079.75-18.02-5.57-3.49
Price to sales ratio
2.482.532.292.20.99
POCF ratio
8.027.4490.54-5.44-3.96
PFCF ratio
8.148.37-8.8-4.42-3.44
P/B Ratio
4.073.022.723.563.2
PTB ratio
4.073.022.723.563.2
EV to sales
2.131.971.972.291.65
Enterprise value over EBITDA
12.95.7777.79-9.14-13.87
EV to operating cash flow
6.95.7977.79-5.64-6.56
EV to free cash flow
7.016.52-7.56-4.58-5.69
Earnings yield
0.070.1-0.06-0.18-0.29
Free cash flow yield
0.120.12-0.11-0.23-0.29
Debt to equity
0.670.490.521.572.78
Debt to assets
0.250.230.240.430.49
Net debt to EBITDA
-2.08-1.64-12.76-0.33-5.5
Current ratio
2.192.651.382.281.91
Interest coverage
5.8111.86-1.36-7.98-7.71
Income quality
2.531.24-0.841.070.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.210.170.150.270.32
Research and developement to revenue
0.210.210.340.480.51
Intangibles to total assets
0.080.080.190.20.2
Capex to operating cash flow
-0.01-0.11-11.290.230.15
Capex to revenue
0-0.04-0.29-0.09-0.04
Capex to depreciation
-0.17-0.78-4.88-1-0.35
Stock based compensation to revenue
00.01-0.0300
Graham number
35.1753.929.9438.6325.62
ROIC
0.180.2-0.05-0.24-0.29
Return on tangible assets
0.120.16-0.08-0.22-0.2
Graham Net
-3.888.441.41-5.01-8.57
Working capital
576.1M760.2M230.3M485.3M349.6M
Tangible asset value
372.2M592.4M324.2M100.8M-23.5M
Net current asset value
248.9M426.5M157.2M-58.6M-179.6M
Invested capital
0.670.490.521.572.78
Average receivables
0136.25M245.15M243.5M289.1M
Average payables
46.6M48.55M48.2M48.1M67.9M
Average inventory
211.9M152.7M120.1M100.35M83.45M
Days sales outstanding
0117.73119.8173.91180.66
Days payables outstanding
101.34170.75261.51227.6308.08
Days of inventory on hand
368.82455.56603.14426.99265.39
Receivables turnover
03.13.052.12.02
Payables turnover
3.62.141.41.61.18
Inventory turnover
0.990.80.610.851.38
ROE
0.290.31-0.15-0.64-0.92
Capex per share
-0.1-0.92-5.51-1.54-0.7

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
4.34.684.544.624.58
Net income per share
-1.04-0.77-2.67-1.86-0.37
Operating cash flow per share
0.42-1.77-1.42-1.79-0.37
Free cash flow per share
0.29-1.81-1.78-1.82-0.68
Cash per share
13.6112.9210.248.127.3
Book value per share
8.998.685.643.763.6
Tangible book value per share
8.998.68-0.683.763.6
Share holders equity per share
8.998.685.643.763.6
Interest debt per share
16.216.5717.6215.7115.11
Market cap
776.64M803.79M620.4M608.23M284.05M
Enterprise value
1.08B1.22B1.03B996.23M550.05M
P/E ratio
-5.44-7.58-1.69-2.38-5.64
Price to sales ratio
5.254.993.983.831.8
POCF ratio
53.56-13.24-12.71-9.87-22.37
PFCF ratio
77.66-12.9-10.17-9.75-12.09
P/B Ratio
2.512.693.24.712.29
PTB ratio
2.512.693.24.712.29
EV to sales
7.297.66.596.273.49
Enterprise value over EBITDA
-33.13-37.76-87.85-24.24100.01
EV to operating cash flow
74.26-20.15-21.06-16.17-43.31
EV to free cash flow
107.67-19.64-16.85-15.97-23.41
Earnings yield
-0.05-0.03-0.15-0.11-0.04
Free cash flow yield
0.01-0.08-0.1-0.1-0.08
Debt to equity
1.761.822.784.114.18
Debt to assets
0.430.450.490.560.56
Net debt to EBITDA
-9.23-12.95-34.82-9.4448.36
Current ratio
2.052.211.911.931.87
Interest coverage
-4.04-1.82-1.54-6.45-4.64
Income quality
-0.291.220.691.040.98
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.350.340.410.420.24
Research and developement to revenue
0.550.480.570.490.48
Intangibles to total assets
0.190.190.20.220.21
Capex to operating cash flow
-0.310.030.250.010.85
Capex to revenue
-0.03-0.01-0.08-0.01-0.07
Capex to depreciation
-0.26-0.09-0.68-0.04-0.58
Stock based compensation to revenue
00000
Graham number
14.4912.2718.4212.545.44
ROIC
-0.05-0.07-0.13-0.08-0.02
Return on tangible assets
-0.03-0.03-0.1-0.09-0.02
Graham Net
-13.16-12.13-8.56-14.81-15.06
Working capital
450.9M452.4M349.6M283.6M264.7M
Tangible asset value
73.4M68.8M-23.5M-78.1M-74M
Net current asset value
-80.1M-77.4M-179.6M-230.9M-234.4M
Invested capital
1.761.822.784.114.18
Average receivables
00154.5M154.5M0
Average payables
0043.3M43.3M0
Average inventory
81M86.55M81.65M69.65M65.9M
Days sales outstanding
00178.2700
Days payables outstanding
00300.9300
Days of inventory on hand
358.3285.11259.23202.89351.1
Receivables turnover
000.500
Payables turnover
000.300
Inventory turnover
0.250.320.350.440.26
ROE
-0.12-0.09-0.47-0.49-0.1
Capex per share
-0.13-0.05-0.36-0.02-0.31

ORXOY Frequently Asked Questions

What is Orexo AB (publ) stock symbol ?

Orexo AB (publ) is a SE stock and trading under the symbol ORXOY

What is Orexo AB (publ) stock quote today ?

Orexo AB (publ) stock price is $0.76 today.

Is Orexo AB (publ) stock public?

Yes, Orexo AB (publ) is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap